Todd Harris - Sep 14, 2021 Form 3 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Chief Executive Officer, Director
Signature
/s/ John Healy, Attorney-in Fact
Stock symbol
TYRA
Transactions as of
Sep 14, 2021
Transactions value $
$0
Form type
3
Date filed
9/14/2021, 09:17 PM
Next filing
Sep 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TYRA Common Stock 1.66M Sep 14, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TYRA Series A Preferred Stock Sep 14, 2021 Common Stock 34K $0.00 Direct F2
holding TYRA Stock Option (Right to Buy) Sep 14, 2021 Common Stock 178K $2.25 Direct F3
holding TYRA Stock Option (Right to Buy) Sep 14, 2021 Common Stock 429K $2.25 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 464,088 shares subject to repurchase by us, which are subject to vesting.
F2 The shares of Series A Preferred Stock are convertible, at any time, at the holder's election, to shares of the Issuer's common stock at a ratio of 1-for-2.5974. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock will automatically convert to shares of the Issuer's common stock at a ratio of 1-for-2.5974. The Series A Preferred Stock has no expiration date.
F3 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.
F4 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney